Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mild Facial Paresis in a Recipient of Gam-Covid-Vac Vaccine: A Case Report Publisher



Mahmoudi Hamidabad N1 ; Mafi AR2 ; Abolmaali M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran

Source: Clinical Medicine Insights: Case Reports Published:2022


Abstract

Facial paralysis has been reported as a rare side effect of mRNA COVID-19 vaccines. The Gam-COVID-Vac was introduced in August 2020 in Russia. There was no report of facial paralysis in phase I to III clinical trials of the vaccine. To our knowledge, there is no post-marketing report of facial paresis with Gam-COVID-Vac vaccination to this date. The Gam-COVID-Vac vaccine has a reported efficacy of 90%, but its safety and efficacy have not been approved by international organizations to this date. Iran is among the countries using the Gam-COVID-Vac vaccine. Here, we present a case of mild facial paresis that occurred shortly after the Gam-COVID-Vac vaccine administration in a female healthcare worker. © The Author(s) 2022.
Related Docs
1. Association of Sars-Cov-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-Analysis, JAMA Otolaryngology - Head and Neck Surgery (2023)
2. Sputnik V Vaccine-Related Complications and Its Impression on Inflammatory Biomarkers in Healthcare Providers, Indian Journal of Medical Microbiology (2023)
Experts (# of related papers)
View all Related Experts
Samaneh Akbarpour (1)
Saeid Nateghi (1)